1.
Tome-Garcia J, Erfani P, Nudelman G, et al. Analysis of chromatin accessibility uncovers TEAD1 as a regulator of migration in human glioblastoma. Nat Commun. 2018;9(1):4020. doi:10.1038/s41467-018-06258-2.
1.
Godlewski J, Ferrer-Luna R, Rooj AK, et al. MicroRNA Signatures and Molecular Subtypes of Glioblastoma: The Role of Extracellular Transfer. Stem Cell Reports. 2017;8(6):1497-1505. doi:10.1016/j.stemcr.2017.04.024.
1.
Wang H, Pan J-Q, Luo L, et al. NF-κB induces miR-148a to sustain TGF-β/Smad signaling activation in glioblastoma. Mol Cancer. 2015;14:2. doi:10.1186/1476-4598-14-2.
1.
Liu D, Abbosh P, Keliher D, et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 2017;8(1):2193. doi:10.1038/s41467-017-02320-7.
1.
Auslander N, Cunningham CE, Toosi BM, et al. An integrated computational and experimental study uncovers FUT9 as a metabolic driver of colorectal cancer. Mol Syst Biol. 2017;13(12):956. doi:10.15252/msb.20177739.
1.
Alexe G, Dalgin GS, Scanfeld D, et al. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res. 2007;67(22):10669-76. doi:10.1158/0008-5472.CAN-07-0539.
1.
Benassi B, Flavin R, Marchionni L, et al. MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer. Cancer Discov. 2012;2(3):236-47. doi:10.1158/2159-8290.CD-11-0219.
1.
Dulak AM, Stojanov P, Peng S, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013;45(5):478-86. doi:10.1038/ng.2591.
1.
Hagerstrand D, Tong A, Schumacher SE, et al. Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov. 2013;3(9):1044-57. doi:10.1158/2159-8290.CD-12-0592.
1.
Li X, Yang H, Huang H, Zhu T. CELLCOUNTER: novel open-source software for counting cell migration and invasion in vitro. Biomed Res Int. 2014;2014:863564. doi:10.1155/2014/863564.